EVALUATION OF MINIMAL RESIDUAL DISEASE IN HIGH-RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA USING AN IMMUNOLOGICAL APPROACH DURING COMPLETE REMISSION

被引:0
|
作者
CONSOLINI, R
SCAMARDELLA, F
LEGITIMO, A
PUTTI, C
GRANCHI, D
PAOLUCCI, P
LIPPI, A
GUAZZELLI, C
ACQUAVIVA, A
ROSANDA, C
BASSO, G
MACCHIA, P
机构
[1] UNIV PADUA, DIPARTIMENTO PEDIAT, I-35100 PADUA, ITALY
[2] UNIV BOLOGNA, PEDIAT CLIN 3, I-40126 BOLOGNA, ITALY
[3] UNIV FLORENCE, PEDIAT CLIN, I-50121 FLORENCE, ITALY
[4] UNIV SIENA, IST CLIN PEDIAT, I-53100 SIENA, ITALY
[5] IST GIOVANNA GASLINI, GENOA, ITALY
关键词
MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; COMPLETE REMISSION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sensitive methods for detecting residual disease may complement conventional morphology while monitoring the response to treatment in leukemia patients. Methods. We studied minimal residual disease (MRD) by selecting via a colony assay a peripheral blood (PB) cell population enriched in putative malignant cells and detecting occult leukemic cells by double immunologic analysis performed on colonyforming cells (CFC). Using this combined technique we assayed the PB of high risk children with acute lymphoblastic leukemia (ALL) in order to demonstrate possible differences in <<the residual tumor cell burden>> among leukemia patients and to correlate these with a 3-year clinical follow-up. Results. In all 22 patients positive results were obtained for up to 18 months following induction chemotherapy at times of apparent hematologic remission. Common ALL (cALL) patients exhibited a mean of 9.6% cAlla+ cells (range: 2% to 30%), whereas cALL antigen (cALLA) and cALLA/Tdt or CDla/Tdt combination were never found in the colonies derived from healthy individuals. Six out of 22 cALL patients expressed a mean of 16.5% cALLA+/Tdt+ CFC (range: 2% to 35%). Five TALL children presented a mean of 24% CD1a/Tdt+ cells (range: 8% to 44%). Extensive follow-up indicates a correlation between the percentage of CFC Tdt+/lymphoid marker+ cells (more than 10%) and subsequent clinical relapse. In one patient relapse occurred after 16 months with a dramatic increase in the number of leukemic cells. In contrast, the decline in malignant cells, observed in two cases, predicted a favourable course. Five patients tested before autologous bone marrow transplantation (ABMT) presented high number of positive cells and relapsed at various times. Conclusions. We conclude that this approach to the study of MRD could be valuable in monitoring the efficacy of chemotherapy, as well in evaluating the quality of purged marrow.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
  • [31] Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
    Coustan-Smith, E
    Sancho, J
    Hancock, ML
    Boyett, JM
    Behm, FG
    Raimondi, SC
    Sandlund, JT
    Rivera, GK
    Rubnitz, JE
    Ribeiro, RC
    Pui, CH
    Campana, D
    BLOOD, 2000, 96 (08) : 2691 - 2696
  • [32] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
    Cavé, H
    ten Bosch, JV
    Suciu, S
    Guidal, C
    Waterkeyn, C
    Otten, J
    Bakkus, M
    Thielemans, K
    Grandchamp, B
    Vilmer, E
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09): : 591 - 598
  • [33] Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
    Xia, Min
    Zhang, Hong
    Lu, Zhenghua
    Gao, Yuan
    Liao, Xuelian
    Li, Hong
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (06) : 418 - 422
  • [34] Clinical implication of minimal residual disease in childhood acute lymphoblastic leukemia
    Yokota, S
    Seriu, T
    Nakao, M
    Iwai, T
    Misawa, S
    INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, 1998, 5 (2-4): : 231 - 249
  • [35] BONE-MARROW ABLATION FOLLOWED BY ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH HIGH-RISK ACUTE LYMPHOBLASTIC-LEUKEMIA DURING COMPLETE REMISSION
    SCOTT, EP
    FORMAN, SJ
    SPRUCE, WE
    KRANCE, RA
    FARBSTEIN, MJ
    WOLF, JL
    NADEMANEE, AP
    FAHEY, JL
    HECHT, T
    BLUME, KG
    TRANSPLANTATION PROCEEDINGS, 1983, 15 (01) : 1395 - 1396
  • [36] Minimal Residual Disease in Ovarian Biopsies Collected in Patients with Bone Marrow Complete Remission of Acute Lymphoblastic Leukemia
    Chevillon, Florian
    Dalle, Jean-Hugues
    Arfeuille, Chloe
    Chalas, Celine
    Passet, Marie
    Drouineaud, Veronique
    Nguyen, Stephanie
    Rahal, Ilhem
    De Latour, Regis Peffault
    Degaud, Michael
    Alcantara, Marion
    Cabannes-Hamy, Aurelie
    Boissel, Nicolas
    Clappier, Emmanuelle
    Poirot, Catherine
    Dhedin, Nathalie
    BLOOD, 2018, 132
  • [37] BONE-MARROW TRANSPLANTATION FOR HIGH-RISK CHILDHOOD LYMPHOBLASTIC-LEUKEMIA
    MCCARTHY, D
    POYNTON, C
    BARRETT, J
    LANCET, 1992, 340 (8826): : 1045 - 1045
  • [38] FAILURE OF INTERMITTENT INTENSIVE PROLONGED CONSOLIDATION THERAPY TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    STARK, B
    SHAG, Y
    VOGEL, R
    COHEN, IJ
    POTAZNICK, D
    KAPLINSKY, C
    DVIR, A
    GOSHEN, Y
    YANIV, I
    MAMMON, Z
    UMIEL, T
    ZAIZOV, R
    MEDICAL AND PEDIATRIC ONCOLOGY, 1988, 16 (06): : 390 - 390
  • [39] Status of Minimal Residual Disease Determines Outcome of Autologous HSCT in Adults with High-Risk Acute Lymphoblastic Leukemia
    Giebel, Sebastian
    Stella-Holowiecka, Beata
    Krawczyk-Kulis, Malgorzata
    Goekbuget, Nicola
    Hoelzer, Dieter
    Doubek, Michael
    Mayer, Jiri
    Piatkowska-Jakubas, Beata
    Skotnicki, Aleksander
    Dombret, Herve
    Ribera, Josep-Maria
    Piccaluga, Pier Paolo
    Czerw, Tomasz
    Sadus-Wojciechowska, Maria
    Kyrcz-Krzemien, Slawomira
    Holowiecki, Jerzy
    BLOOD, 2009, 114 (22) : 917 - 917
  • [40] Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia
    Paganin, M.
    Zecca, M.
    Fabbri, G.
    Polato, K.
    Biondi, A.
    Rizzari, C.
    Locatelli, F.
    Basso, G.
    LEUKEMIA, 2008, 22 (12) : 2193 - 2200